Peer Review reports
From: Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
| Original Submission | ||
|---|---|---|
| 19 Sep 2022 | Submitted | Original manuscript |
| 10 Nov 2022 | Reviewed | Reviewer Report |
| 22 Nov 2022 | Reviewed | Reviewer Report |
| 8 Dec 2022 | Author responded | Author comments - Erik Ehinger |
| Resubmission - Version 2 | ||
| 8 Dec 2022 | Submitted | Manuscript version 2 |
| 9 Dec 2022 | Author responded | Author comments - Erik Ehinger |
| Resubmission - Version 3 | ||
| 9 Dec 2022 | Submitted | Manuscript version 3 |
| 12 Dec 2022 | Author responded | Author comments - Erik Ehinger |
| Resubmission - Version 4 | ||
| 12 Dec 2022 | Submitted | Manuscript version 4 |
| Publishing | ||
| 13 Feb 2023 | Editorially accepted | |
| 18 Feb 2023 | Article published | 10.1186/s12883-023-03119-4 |
You can find further information about peer review here.